Study: Countries angling to lure U.S. biopharma companies

In a study commissioned by PhRMA, Battelle reports that countries around the globe are boosting their investments in R&D and instituting innovation-friendly policies to attract biopharma outfits. PhRMA CEO John Castellani said in a statement that regulatory uncertainty and strict IP laws could put the U.S. at a disadvantage, leading big-earning biopharma companies to flee overseas. Castellani points to Germany, which used to be "the world's medicine cabinet," and cautions that if the U.S. government doesn't reaffirm its commitment to biomedical innovation, it could lose its standing in the industry. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.